Association Study between Functional Polymorphisms of MMP9 Gene Promoter and Multiple Sclerosis Susceptibility in an Iranian Population
-
Sima SABBAGH
,
Zakiye NADEALI
,
Leila DEHGHANI
,
Vahid SHAYGANNEJAD
,
Majid REZVANI
,
Masih SABOORI
,
Hamid GANJI
,
Soheil TAHANI
,
Farzaneh DEHGHANI
,
Saman HOSSEINZADEH
,
Elnaz MARZBANI
,
Peiman SHAFIEI
Abstract
Background: Matrix metalloproteinase-9 (MMP-9) polymorphisms, C−1562 T and -90 (CA) n repeats, which influence transcriptional activity of this gene, are proposed to play a role in MS susceptibility and its development. In the present study, the possible association of MMP-9 polymorphisms in Iranian MS patients is studied.
Methods: Association of MMP-9 mentioned gene polymorphisms with MS susceptibility was evaluated in unrelated Iranian subjects referred to Al-Zahra Hospital, Isfahan, Iran during 2014 to 2017.
Results: -1562 T allele of MMP-9 was associated with increased MS risk. However, we found no overall significant effect of −90 (CA)n repeat on MS susceptibility.
Conclusion: For as much as MMP-9 molecule is a potential target for MS therapy, to determine whether any of MMP-9 polymorphisms influence MS susceptibility in Iranian MS patients or not, concerning the significant influence of T allele on MS susceptibility and the non-significant association regarding CA repeats, further research is needed before proposing any definite conclusion.
1. Sergio EB, Jorge RO (2017). The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. Trends GenetT, 33(12):960-970.
2. Stephen S, Robin J MF, Maria B (2014). Multiple sclerosis genetics. Lancet Neurol, 13:700-709.
3. Brosnan CF, Raine CS (1996). Mechanisms of Immune Injury in Multiple Sclerosis. Brain Pathol, 6:243-257.
4. Dehghani L, Meamar R, Etemadifar M et al (2013). Can Vitamin D Suppress Endothelial Cells Apoptosis in Multiple Sclerosis Patients? Int J Prev Med, 4:S211-S215.
5. Waubant E (2006). Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers, 22:235–244.
6. Yong VW, Power C, Forsyth P, Edwards DR (2001). Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci, 2:502-511.
7. Woessner JF Jr (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J, 5:2145-2154.
8. Chandler S, Coatesb R, Gearinga A et al (1995). Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett, 21:223–226.
9. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G (1993). Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res, 36:432-40.
10. Proost P, Vandamme J, Opdenakker G (1993). Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun, 192:1175-1181.
11. Gijbels K, Masure S, Carton H, Opdenakker G (1992). Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol, 41:29-34.
12. Paemen L, Olsson T, Söderström M et al (1994). Evaluation of gelatinases and IL‐6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol, 1:55-63.
13. Comabella M, Río J, Espejo C et al (2009). Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol, 130:145-150.
14. Benešová Y, Vašků A, Novotná H, Litzman J et al (2009). Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler, 15(3)316-:22.
15. Fernandes KSS, Brum DG, Sandrim VC et al (2009). Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol, 214:128-131.
16. La Russa A, Cittadella R, De Marco EV et al (2010). Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroimmunol, 225:175–179.
17. Shimajiri S, Arima N, Tanimoto A et al (1999). Shortened microsatellite d (CA) 21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett, 455:70-74.
18. Zhang B, Ye S, Herrmann S-M, Eriksson P et al (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99:1788-1794.
19. Fiotti N, Zivadinov R, Altamura N et al (2004). MMP-9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol, 152:147–153
20. Peters DG, Kassam A, Jean PLS (1999). Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke, 30:2612-2616.
21. Zhang B, Henney A, Eriksson P et al (1999). Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12. 2–13.1. Hum Genet, 105:418-423.
22. Fernandes KSdS, Brum DG, Palei AC (2012). Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients. J Neuroimmunol, 249:56–59
23. Waubant E, Goodkin D, Gee L, Bacchetti P et al (1999). Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology, 53:1397-1401.
24. Nelissen I, Vandenbroeck K, Fiten P (2000). Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol, 105:58-63.
25. Yoon S, Tromp G, Vongpunsawad S (1999). Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun, 265:563-568.
26. Benešová' Y, Vašků A, Štourač P (2008). Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol, 205:105–109.
27. Nischwitz S, Wolf C, Andlauer T et al (2015). MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene. J Neuroimmunol, 279:46–49
28. Živković M, Djurić T, Dinčić E (2007). Matrix metalloproteinase-9− 1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. J Neuroimmunol, 189:147–150.
29. Jing L, Shuang -YL, Yan-Bo L et al (2017). Association Study of MMP-9 1562C/T Gene Polymorphism with Susceptibility to Multiple Autoimmune Diseases: A Meta-analysis. Arch Med Res, 48:105-112.
2. Stephen S, Robin J MF, Maria B (2014). Multiple sclerosis genetics. Lancet Neurol, 13:700-709.
3. Brosnan CF, Raine CS (1996). Mechanisms of Immune Injury in Multiple Sclerosis. Brain Pathol, 6:243-257.
4. Dehghani L, Meamar R, Etemadifar M et al (2013). Can Vitamin D Suppress Endothelial Cells Apoptosis in Multiple Sclerosis Patients? Int J Prev Med, 4:S211-S215.
5. Waubant E (2006). Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers, 22:235–244.
6. Yong VW, Power C, Forsyth P, Edwards DR (2001). Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci, 2:502-511.
7. Woessner JF Jr (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J, 5:2145-2154.
8. Chandler S, Coatesb R, Gearinga A et al (1995). Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett, 21:223–226.
9. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G (1993). Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res, 36:432-40.
10. Proost P, Vandamme J, Opdenakker G (1993). Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun, 192:1175-1181.
11. Gijbels K, Masure S, Carton H, Opdenakker G (1992). Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol, 41:29-34.
12. Paemen L, Olsson T, Söderström M et al (1994). Evaluation of gelatinases and IL‐6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol, 1:55-63.
13. Comabella M, Río J, Espejo C et al (2009). Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol, 130:145-150.
14. Benešová Y, Vašků A, Novotná H, Litzman J et al (2009). Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler, 15(3)316-:22.
15. Fernandes KSS, Brum DG, Sandrim VC et al (2009). Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol, 214:128-131.
16. La Russa A, Cittadella R, De Marco EV et al (2010). Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroimmunol, 225:175–179.
17. Shimajiri S, Arima N, Tanimoto A et al (1999). Shortened microsatellite d (CA) 21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett, 455:70-74.
18. Zhang B, Ye S, Herrmann S-M, Eriksson P et al (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99:1788-1794.
19. Fiotti N, Zivadinov R, Altamura N et al (2004). MMP-9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol, 152:147–153
20. Peters DG, Kassam A, Jean PLS (1999). Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke, 30:2612-2616.
21. Zhang B, Henney A, Eriksson P et al (1999). Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12. 2–13.1. Hum Genet, 105:418-423.
22. Fernandes KSdS, Brum DG, Palei AC (2012). Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients. J Neuroimmunol, 249:56–59
23. Waubant E, Goodkin D, Gee L, Bacchetti P et al (1999). Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology, 53:1397-1401.
24. Nelissen I, Vandenbroeck K, Fiten P (2000). Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol, 105:58-63.
25. Yoon S, Tromp G, Vongpunsawad S (1999). Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun, 265:563-568.
26. Benešová' Y, Vašků A, Štourač P (2008). Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol, 205:105–109.
27. Nischwitz S, Wolf C, Andlauer T et al (2015). MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene. J Neuroimmunol, 279:46–49
28. Živković M, Djurić T, Dinčić E (2007). Matrix metalloproteinase-9− 1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. J Neuroimmunol, 189:147–150.
29. Jing L, Shuang -YL, Yan-Bo L et al (2017). Association Study of MMP-9 1562C/T Gene Polymorphism with Susceptibility to Multiple Autoimmune Diseases: A Meta-analysis. Arch Med Res, 48:105-112.
| Files | ||
| Issue | Vol 48 No 9 (2019) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v48i9.3030 | |
| Keywords | ||
| Multiple sclerosis MMP-9 gene Polymorphism Association study | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
SABBAGH S, NADEALI Z, DEHGHANI L, SHAYGANNEJAD V, REZVANI M, SABOORI M, GANJI H, TAHANI S, DEHGHANI F, HOSSEINZADEH S, MARZBANI E, SHAFIEI P. Association Study between Functional Polymorphisms of MMP9 Gene Promoter and Multiple Sclerosis Susceptibility in an Iranian Population. Iran J Public Health. 2019;48(9):1697-1703.
